Irreversible inhibition of serine proteases - Design and in vivo activity of diaryl α-aminophosphonate derivatives

Current Medicinal Chemistry

Volumn 16, Issue 13, 2009, Pages 1673-1687

  Sienczyk M ^a   Oleksyszyn, Jozef ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

aminophosphonate diphenyl esters; Activity based probes; Catalytic antibodies; Enzyme inhibitors; Serine proteases

Indexed keywords

AB 192; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA AMINOPHOSPHONATE DIARYL ESTER; APTAMER; BIOTIN; CHYMOTRYPSIN INHIBITOR; DIPEPTIDE PROLINE DIPHENYL PHOSPHONATE GLYCINE PRODIPINE; DIPEPTIDYL PEPTIDASE I; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; HERPESVIRUS PROTEASE; LEUKOCYTE ELASTASE INHIBITOR; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; NX 21909; PHOSPHONIC ACID INHIBITOR; PRODIPINE; RWJ 58643; SEPRASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SUCCINYLVALYLPROLYLPHENYLALANINE; TALABOSTAT; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE RECEPTOR; UROKINASE RECEPTOR 1; VIRUS PROTEIN; PHOSPHONIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ASTHMA; BREAST ADENOCARCINOMA; CANCER GROWTH; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; INTRAOCULAR HYPERTENSION; MAST CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE ALLERGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; ARTICLE; CATALYSIS;

CATALYSIS; DRUG DESIGN; HUMANS; PHOSPHONIC ACIDS; SERINE PROTEINASE INHIBITORS;

EID: 67650230587     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186246     Document Type: Review

References (107)

1. Oleksyszyn, J.; Subotkowska, L.; Mastalerz, P. Diphenyl 1-aminoalkanephosphonates. Synthesis, 1979, 12, 985-6.
2. Yuan, C.; Wang, G.; Chen, S. Studies on organophosphorus compounds; XLVI. A Facile and Direct Route to Dialkyl 1-(Benzyloxycarbonylamino) alkylphosphonates and Dialkyl or Diphenyl α-(Benzyloxycarbonylamino)benzylphosphonates. Synthesis, 1990, 4, 522-4.
3. Van der Veken, P.; El Sayed, I.; Joossens, J.; Stevens, C.V.; Augustyns, K.; Haemers, A. Lewis Acid Catalyzed Synthesis of N-Protected Diphenyl 1-Aminoalkyl-phosphonates. Synthesis, 2005, 4, 634-8.
4. Umezaki, M.; Fujii, T.; Yoshimura, T.; Yamazaki, I.; Ono, S. PEG-inhibitor conjugates: Application of diphenyl alpha-aminoalkylphosphonate to removal of chymotrypsin. Biotechnol. Biochem., 2003, 67, 2273-6.
5. Kafarski, P.; Lejczak, B. Aminophosphonic acids of potential medical importance. Curr. Med. Chem. Anticancer Agents, 2001, 1, 301-12.
6. Oleksyszyn, J.; Powers, J.C. Irreversible inhibition of serine proteases by peptidyl derivatives of alpha-aminoalkylphosphonate diphenyl esters. Biochem. Biophys. Res. Commun., 1989, 161, 143-.
7. Oleksyszyn, J.; Powers, J.C. Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry, 1991, 30, 485-93.
8. Oleksyszyn, J. In Aminophosphonic and aminophosphinic acids. Chemistry and biological activity; Kukhar, V.P.; Hudson, H.R.; Eds.; John Wiley & Sons, 2000; pp. 537-57.
9. Oleksyszyn, J.; Powers, J.C. In Methods in Enzymology; Barrett, A.J.; Ed.; Academic Press, 1994; Vol. 244, pp. 423-41.
10. Dano, K.; Andreasen, P.A.; Grondahl-Hansen, J.; Kristensen, P.; Nielsen, L.S.; Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 1985, 44, 139-266.
11. Dass, K.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Sarkar, F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev., 2008, 34, 122-36.
12. Torrisani, J.; Bournet, B.; Cordelier, P.; Buscail, L. New molecular targets in pancreatic cancer. Bull. Cancer, 2008, 95, 503-12.
13. Dano, K.; Behrendt, N.; Hoyer-Hansen, G.; Johnsen, M.; Lund, L.R.; Ploug, M.; Romer, J. Plasminogen activation and cancer. Thromb. Haemost., 2005, 93, 676-81.
14. Fastrez, J.; Jespers, L.; Lison, D.; Renard, M.; Sonveaux, E. Synthesis of new phosphonate inhibitors of serine proteases. Tetrahedron Lett., 1989, 30, 6861-4.
15. Joossens, J.; Van der Veken, P.; Lambeir, A.M.; Augustyns, K.; Haemers, A. Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator. J. Med. Chem., 2004, 47, 2411-3.
16. Tamura, S.Y.; Weinhouse, M.I.; Roberts, C.A.; Goldman, E.A.; Masukawa, K.; Anderson, S.M.; Cohen, C.R.; Bradbury, A.E.; Bernardino, V.T.; Dixon, S.A.; Ma, M.G.; Nolan, T.G.; Brunck, T.K. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 983-7.
17. Joossens, J.; Van der Veken, P.; Surpateanu, G.; Lambeir, A.M.; El-Sayed, I.; Ali, O.M.; Augustyns, K.; Haemers, A. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: Optimization of the P4 position. J. Med. Chem., 2006, 49, 5785- 3.
18. Sienczyk, M.; Oleksyszyn, J. Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: The influence of the ester group on their biological activity. Bioorg. Med. Chem. Lett., 2006, 16, 2886-90.
19. Sienczyk, M.; Oleksyszyn, J. A convenient synthesis of new α-aminoalkylphosphonates, aromatic analogues of arginine as inhibitors of trypsin-like enzymes. Tetrahedron Lett., 2004, 45, 7251-4.
20. Pietrusewicz, E.; Sienczyk, M.; Oleksyszyn, J. Novel diphenyl esters of peptidyl ..-aminoalkylphosphonates as inhibitors of chymotrypsin and subtilisin. J. Enz. Inh. Med. Chem., 2008, in press
21. Jankun, J.; Oleksyszyn, J.; Sienczyk, M.; unpublished results.
22. Vilen, S.T.; Nyberg, P.; Hukkanen, M.; Sutinen, M.; Ylipalosaari, M.; Bjartell, A.; Paju, A.; Haaparanta, V.; Stenman, U.H.; Sorsa, T.; Salo, T. Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: Possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. Exp. Cell Res., 2008, 314, 914-26.
23. Falanga, A. Thrombophilia in cancer. Semin. Thromb. Hemost., 2005, 31, 104-10.
24. Ornstein, D.L.; Meehan, K.R.; Zacharski, L.R. The coagulation system as a target for the treatment of human gliomas. Semin. Thromb. Hemost., 2002, 28, 19-28.
25. Joossens, J.; Ali, O.M.; El-Sayed, I.; Surpateanu, G.; Van der Veken, P.; Lambeir, A.M.; Setyono-Han, B.; Foekens, J.A.; Schneider, A.; Schmalix, W.; Haemers, A.; Augustyns, K. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J. Med. Chem., 2007, 50, 6638-46.
26. Moraes, T.J.; Chow, C.W.; Downey, G.P. Proteases and lung injury. Crit. Care Med., 2003, 31, S189-94.
27. Horwitz, M.; Li, F.Q.; Albani, D.; Duan, Z.; Person, R.E.; Meade-White, K.; Benson, K.F. Leukemia in severe congenital neutropenia: Defective proteolysis suggests new pathways to malignancy and opportunities for therapy. Cancer Invest., 2003, 21, 579-87.
28. Macnee, W. Pathogenesis of chronic obstructive pulmonary disease. Clin. Chest. Med., 2007, 28, 479-513.
29. Mainardi, C.L.; Dixit, S.N.; Kang, A.H. Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules. J. Biol. Chem., 1980, 255, 5435-41.
30. McDonald, J.A.; Kelley, D.G. Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. J. Biol. Chem., 1980, 255, 8848-58.
31. Stockley, R.A.; Hill, S.L.; Burnett, D. Proteinases in chronic lung infection. Ann. N. Y. Acad. Sci., 1991, 624, 257-66.
32. Mueller, S.G.; Paterson, A.J.; Kudlow, J.E. Transforming growth factor alpha in arterioles: Cell surface processing of its precursor by elastases. Mol. Cell Biol., 1990, 10, 4596-602
33. Nakamura, H.; Yoshimura, K.; McElvaney, N.G.; Crystal, R.G. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest., 1992, 89, 1478-84.
34. Travis, J.; Salvesen, G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem., 1983, 52, 655-709.
35. Thompson, R.C.; Ohlsson, K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. U.S.A., 1986, 83, 6692-6.
36. Silverman, G.A.; Bird, P.I.; Carrell, R.W.; Church, F.C.; Coughlin, P.B.; Gettins, P.G.; Irving, J.A.; Lomas, D.A.; Luke, C.J.; Moyer, R.W.; Pemberton, P.A.; Remold-O'Donnell, E.; Salvesen, G.S.; Travis, J.; Whisstock, J.C. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem., 2001, 276, 33293-6.
37. Sato, T.; Takahashi, S.; Mizumoto, T.; Harao, M.; Akizuki, M.; Takasugi, M.; Fukutomi, T.; Yamashita, J. Neutrophil elastase and cancer. Surg. Oncol., 2006, 15, 217-22.
38. Yamashita, J.I.; Ogawa, M.; Ikei, S.; Omachi, H.; Yamashita, S.I.; Saishoji, T.; Nomura, K.; Sato, H. Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer. Br. J. Cancer, 1994, 69, 72-6.
39. Yamashita, J.; Tashiro, K.; Yoneda, S.; Kawahara, K.; Shirakusa, T. Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest, 1996, 109, 1328-34.
40. Boduszek, B.; Brown, A.D.; Powers, J.C. Alpha-Aminoalkyl-phosphonate di(chlorophenyl) esters as inhibitors of serine proteases. J. Enzyme Inhib., 1994, 8, 147-58.
41. Sienczyk, M.; Winiarski, L.; Oleksyszyn, J. 2008, Polish Patent Application.
42. Sienczyk, M.; Kliszczak, M.; Oleksyszyn, J. Synthesis of isocyanide derivatives of α-aminoalkylphosphonate diphenyl esters. Tetrahedron Lett., 2006, 47, 4209-11.
43. Charlton, J.; Kirschenheuter, G.P.; Smith, D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry, 1997, 36, 3018-26.
44. Bless, N.M.; Smith, D.; Charlton, J.; Czermak, B.J.; Schmal, H.; Friedl, H.P.; Ward, P.A. Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury. Curr. Biol., 1997, 7, 877-80.
45. Gordon, J.R.; Burd, P.R.; Galli, S.J. Mast cells as a source of multifunctional cytokines. Immunol. Today, 1990, 11, 458-64.
46. Caughey, G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol. Rev., 2007, 217, 141-54.
47. Caughey, G.H. Tryptase genetics and anaphylaxis. J. Allergy Clin. Immunol., 2006, 117, 1411-4.
48. Numerof, R.P.; Simpson, P.J.; Tanaka, R. Tryptase inhibitors: A novel class of anti-inflammatory drugs. Expert Opin. Investig. Drugs, 1997, 6, 811-7.
49. Krishna, M.T.; Chauhan, A.; Little, L.; Sampson, K.; Hawksworth, R.; Mant, T.; Djukanovic, R.; Lee, T.; Holgate, S. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol., 2001, 107, 1039-45.
50. Erin, E.M.; Leaker, B.R.; Zacharasiewicz, A.; Higgins, L.A.; Nicholson, G.C.; Boyce, M.J.; de Boer, P.; Jones, R.C.; Durham, S.R.; Barnes, P.J.; Hansel, T.T. Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin. Exp. Allergy, 2006, 36, 458-64.
51. Costanzo, M.J.; Yabut, S.C.; Almond, H.R. Jr.; Andrade-Gordon, P.; Corcoran, T.W.; De Garavilla, L.; Kauffman, J.A.; Abraham, W.M.; Recacha, R.; Chattopadhyay, D.; Maryanoff, B.E. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone. J. Med. Chem., 2003, 46, 3865-76.
52. Pejler, G.; Berg, L. Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan. Eur. J. Biochem., 1995, 233, 192-9.
53. Lindstedt, L.; Lee, M.; Kovanen, P.T. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis, 2001, 155, 87-97.
54. Muto, T.; Fukami, H. Recent chymase inhibitors and their effects in in vivo models. IDrugs, 2002, 5, 1141-50
55. Han, Y.P.; Nien, Y.D.; Garner, W.L. Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J. Biol. Chem., 2002, 277, 27319-27.
56. Shiota, N.; Kakizoe, E.; Shimoura, K.; Tanaka, T.; Okunishi, H. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br. J. Pharmacol., 2005, 145, 424-31.
57. Kondo, K.; Muramatsu, M.; Okamoto, Y.; Jin, D.; Takai, S.; Tanigawa, N.; Miyazaki, M. Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J. Surg. Oncol., 2006, 93, 36-42.
58. Takai, S.; Miyazaki, M. A novel therapeutic strategy against vascular disorders with chymase inhibitor. Curr. Vasc. Pharmacol., 2003, 1, 217-224.
59. Takai, S.; Jin, D.; Muramatsu, M.; Okamoto, Y.; Miyazaki, M. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur. J. Pharmacol., 2004, 501, 1-8.
60. Miyazaki, M.; Takai, S.; Jin, D.; Muramatsu, M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol. Ther., 2006, 112, 668-76.
61. Konno, T.; Maruichi, M.; Takai, S.; Oku, H.; Sugiyama, T.; Uchibori, T.; Nagai, A.; Kogi, K.; Ikeda, T.; Miyazaki, M. Effect of chymase on intraocular pressure in rabbits. Eur. J. Pharmacol., 2005, 524, 132-7.
62. Takai, S.; Yuda, A.; Jin, D.; Nishimoto, M.; Sakagichi, M.; Sasaki, S.; Miyazaki, M. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett., 2000, 467, 141-4.
63. Okamoto, Y.; Takai, S.; Miyazaki, M. Chymase inhibitor suppresses adhesion formation in a hamster experimental model. Eur. J. Pharmacol., 2002, 435, 265-7.
64. Okamoto, Y.; Takai, S.; Yamada, M.; Miyazaki, M. Chymase inhibitors may prevent postoperative adhesion formation. Fertil. Steril., 2002, 77, 1044-8.
65. Maruichi, M.; Takai, S.; Sugiyama, T.; Ueki, M.; Oku, H.; Sakaguchi, M.; Okamoto, Y.; Muramatsu, M.; Ikeda, T.; Miyazaki, M. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp. Eye Res., 2004, 79, 111-8.
66. Van der Veken, P.; Haemers, A.; Augustyns, K. Prolyl peptidases related to dipeptidyl peptidase IV: Potential of specific inhibitors in drug discovery. Curr. Top Med. Chem., 2007, 7, 621-35
67. Morimoto, C.; Schlossman, S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev., 1998, 161, 55-70.
68. Flatt, P.R.; Bailey, C.J.; Green, B.D. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front. Biosci., 2008, 13, 3648-60.
69. Augustyns, K.; Van der Veken, P.; Haemers, A. Inhibitors of proline-specific a dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of type 2 diabetes. Expert Opinin. Ther. Patents, 2005, 15, 1387-407.
70. Thomas, W.G.; Caldwell, E.; Powers, J.C.; Kam, C.M.; Oleksyszyn, J.; Bray, R.A.; In 16th Annual Meeting of The American Society for Histocompatibility and Immunogenetics, Centry City, California; 1990, Abstract#72.
71. Boduszek, B.; Oleksyszyn, J.; Kam, C.M.; Selzler, J.; Smith, R.E.; Powers, J.C. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J. Med. Chem., 1994, 37, 3969-76
72. Belyaev, A.; Zhang, X.; Augustyns, K.; Lambeir, A.M.; De Meester, I.; Vedernikova, I.; Scharpe, S.; Haemers, A. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem., 1999, 42, 1041-52.
73. Korom, S.; De Meester, I.; Stadlbauer, T.H.; Chandraker, A.; Schaub, M.; Sayegh, M.H.; Belyaev, A.; Haemers, A.; Scharpe, S.; Kupiec-Weglinski, J.W. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation, 1997, 63, 1495-500.
74. Jung, F.J.; Yang, L.; De Meester, I.; Augustyns, K.; Cardell, M.; Hillinger, S.; Vogt, P.; Lardinois, D.; Scharpe, S.; Weder, W.; Korom, S. CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. J. Heart Lung Transplant., 2006, 25, 1109-16.
75. Zhai, W.; Cardell, M.; De Meester, I.; Augustyns, K.; Hillinger, S.; Inci, I.; Arni, S.; Jungraithmayr, W.; Scharpe, S.; Weder, W.; Korom, S. Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. J. Heart Lung Transplant., 2007, [ 26, 174-80.
76. De Meester, I.; Belyaev, A.; Lambeir, A.M.; De Meyer, G.R.; Van Osselaer, N.; Haemers, A.; Scharpe, S. In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). Biochem. Pharmacol., 1997, 54, 173-9
77. Zhai, W.; Cardell, M.; De Meester, I.; Augustyns, K.; Hillinger, S.; Inci, I.; Arni, S.; Jungraithmayr, W.; Scharpe, S.; Weder, W.; Korom, S. Ischemia/reperfusion injury: The role of CD26/ dipeptidyl-peptidase-IV-inhibition in lung transplantation. Transplant. Proc., 2006, 38, 3369-71.
78. Focosi, D.; Kast, R.E.; Metelli, M.R.; Benedetti, E.; Galimberti, S.; Papineschi, F.; Petrini, M. Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure. Leuk. Res., 2009, 33, 178-81.
79. Gilmore, B.F.; Lynas, J.F.; Scott, C.J.; McGoohan, C.; Martin, L.; Walker, B. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha). Biochem. Biophys. Res. Commun., 2006, 346, 436-46.
80. Waxman, L.; Darke, P.L. The herpesvirus proteases as targets for antiviral chemotherapy. Antivir. Chem. Chemother., 2000, 11, 1-22.
81. Marnett, A.B.; Nomura, A.M.; Shimba, N.; Ortiz de Montellano, P.R.; Craik, C.S. Communication between the active sites and dimer interface of a herpesvirus protease revealed by a transitionstate inhibitor. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 6870-5.
82. Ogilvie, W.; Bailey, M.; Poupart, M.A.; Abraham, A.; Bhavsar, A.; Bonneau, P.; Bordeleau, J.; Bousquet, Y.; Chabot, C.; Duceppe, J.S.; Fazal, G.; Goulet, S.; Grand-Maitre, C.; Guse, I.; Halmos, T.; Lavallee, P.; Leach, M.; Malenfant, E.; O'Meara, J.; Plante, R.; Plouffe, C.; Poirier, M.; Soucy, F.; Yoakim, C.; Deziel, R. Peptidomimetic inhibitors of the human cytomegalovirus protease. J. Med. Chem., 1997, 40, 4113-35.
83. Lazic, A.; Goetz, D.H.; Nomura, A.M.; Marnett, A.B.; Craik, C.S. Substrate modulation of enzyme activity in the herpesvirus protease family. J. Mol. Biol., 2007, 373, 913-23.
84. Cravatt, B.F.; Wright, A.T.; Kozarich, J.W. Activity-based protein profiling: From enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem., 2008, 77, 383-414.
85. Abuelyaman, A.S.; Hudig, D.; Woodard, S.L.; Powers, J.C. Fluorescent derivatives of diphenyl [1-(N-peptidylamino)alkyl] phosphonate esters: synthesis and use in the inhibition and cellular localization of serine proteases. Bioconjug. Chem., 1994, 5, 400-5.
86. Abuelyaman, A.S.; Jackson, D.S.; Hudig, D.; Woodard, S.L.; Powers, J.C. Synthesis and kinetic studies of diphenyl 1-(N-peptidylamino) alkanephosphonate esters and their biotinylated derivatives as inhibitors of serine proteases and probes for lymphocyte granzymes. Arch. Biochem. Biophys., 1997, 344, 271-80.
87. Woodard, S.L.; Jackson, D.S.; Abuelyaman, A.S.; Powers, J.C.; Winkler, U.; Hudig, D. Chymase-directed serine protease inhibitor that reacts with a single 30-kDa granzyme and blocks NK-mediated cytotoxicity. J. Immunol., 1994, 153, 5016-25.
88. Hawthorne, S.; Hamilton, R.; Walker, B.J.; Walker, B. Utilization of biotinylated diphenyl phosphonates for disclosure of serine proteases. Anal. Biochem., 2004, 326, 273-5.
89. Mahrus, S.; Craik, C.S. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem. Biol., 2005, 12, 567-77.
90. Pan, Z.; Jeffery, D.A.; Chehade, K.; Beltman, J.; Clark, J.M.; Grothaus, P.; Bogyo, M.; Baruch, A. Development of activity-based probes for trypsin-family serine proteases. Bioorg. Med. Chem. Lett., 2006, 16, 2882-5.
91. Gilmore, B.F.; Carson, L.; McShane, L.L.; Quinn, D.; Coulter, W.A.; 0Walker, B. Synthesis, kinetic evaluation, and utilization of a biotinylated dipeptide proline diphenyl phosphonate for the disclo sure of dipeptidyl peptidase IV-like serine proteases. Biochem. Biophys. Res. Commun., 2006, 347, 373-9.
92. Jakobsen, R.K.; Ono, S.; Powers, J.C.; DeLotto, R. Fluorescently labeled inhibitors detect localized serine protease activities in Drosophila melanogaster pole cells, embryos, and ovarian egg chambers. Histochem. Cell Biol., 2005, 123, 51-60.
93. Morty, R.E.; Troeberg, L.; Powers, J.C.; Ono, S.; Lonsdale-Eccles, J.D.; Coetzer, T.H. Characterisation of the antitrypanosomal activity of peptidyl alpha-aminoalkyl phosphonate diphenyl esters. Biochem. Pharmacol., 2000, 60, 1497-504.
94. Pauling, L. Molecular architecture and biological reactions. Chem. Eng. News, 1946, 24, 1375-7.
95. Paul, S.; Nishiyama, Y.; Planque, S.; Karle, S.; Taguchi, H.; Hanson, C.; Weksler, M.E. Antibodies as defensive enzymes. Springer Semin. Immunopathol., 2005, 26, 485-503.
96. Nevinsky, G.A.; Buneva, V.N. Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases. J. Cell Mol. Med., 2003, 7, 265-76.
97. Wentworth, P. Jr.; Jones, L.H.; Wentworth, A.D.; Zhu, X.; Larsen, N.A.; Wilson, I.A.; Xu, X.; Goddard, W.A.; 3rd; Janda, K.D.; Eschenmoser, A.; Lerner, R.A. Antibody catalysis of the oxidation of water. Science, 2001, 293, 1806-11.
98. Paul, S.; Nishiyama, Y.; Planque, S.; Taguchi, H. Theory of proteolytic antibody occurrence. Immunol. Lett., 2006, 103, 8-16.
99. Paul, S.; Karle, S.; Planque, S.; Taguchi, H.; Salas, M.; Nishiyama, Y.; Handy, B.; Hunter, R.; Edmundson, A.; Hanson, C. Naturally occurring proteolytic antibodies: Selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J. Biol. Chem., 2004, 279, 39611-9
100. Taguchi, H.; Planque, S.; Nishiyama, Y.; Symersky, J.; Boivin, S.; Szabo, P.; Friedland, R.P.; Ramsland, P.A.; Weksler, M.E.; Paul, S. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem., 2008, 283, 4714-22.
101. Deng, S.X.; de Prada, P.; Landry, D.W. Anticocaine catalytic antibodies. J. Immunol. Methods, 2002, 269, 299-310.
102. Taguchi, H.; Planque, S.; Nishiyama, Y.; Szabo, P.; Weksler, M.E.; Friedland, R.P.; Paul, S. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun. Rev., 2008, 7, 391-7.
103. Planque, S.; Nishiyama, Y.; Taguchi, H.; Salas, M.; Hanson, C.; Paul, S. Catalytic antibodies to HIV: Physiological role and potential clinical utility. Autoimmun. Rev., 2008, 7, 473-9.
104. Lacroix-Desmazes, S.; Bayry, J.; Kaveri, S.V.; Hayon-Sonsino, D.; Thorenoor, N.; Cherpentier, J.; Luyt, C.E.; Mira, J.P.; Nagaraja, V.; Kazatchkine, M.D.; Dhainaut, J.F.; Mallet, V.O. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 4109-13.
105. Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 1998, 393, 648-59.
106. Paul, S.; Planque, S.; Zhou, Y.X.; Taguchi, H.; Bhatia, G.; Karle, S.; Hanson, C.; Nishiyama, Y. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J. Biol. Chem., 2003, 278, 20429-35.
107. Planque, S.; Escobar, M.A.; Smith, K.C.; Taguchi, H.; Nishiyama, Y.; Donnachie, E.; Pratt, K.P.; Paul, S. Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII analog. J. Biol. Chem., 2008, 283, 11876-86.